COMMUNIQUÉS West-GlobeNewswire

-
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024 -
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
06/12/2024 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024 -
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
06/12/2024 -
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/12/2024 -
NOTICE OF A GENERAL MEETING OF IBA SA
06/12/2024 -
IBA - Information réglementée
06/12/2024 -
IBA - Regulated Information
06/12/2024 -
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
06/12/2024 -
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
06/12/2024 -
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06/12/2024 -
Spineway provides an update on its activities during a webinar - Arrival of a new CFO
06/12/2024 -
SPINEWAY fait un point d’activité lors d’un webinaire - Arrivée d’un nouveau directeur financier
06/12/2024 -
Virbac : Declaration of the number of shares and voting rights 11/2024
06/12/2024 -
Virbac : Déclaration d'actions et de droits de vote 11/2024
06/12/2024 -
CHEO Research Institute and Shriners Hospitals for Children Canada Collaborate to Launch First-of-its-kind Joint Pediatric Metabolic and Genetic Bone Disorders Fellowship
06/12/2024 -
L'Institut de recherche du CHEO et les Hôpitaux Shriners pour enfants Canada collaborent en lançant le premier programme de Monitorat clinique conjoint sur les troubles métaboliques et génétiques de l’os chez l'enfant
06/12/2024 -
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
06/12/2024 -
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
06/12/2024
Pages